A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)

Summary

This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the treatment of adults with Major Depressive Disorder with Treatment Resistant Depression.

Timeline

Start

2017-09-14

Primary completion

2019-03-31

Completion

2019-06-15

Drugs

Indications